Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709771 · ClinicalTrials.gov registry record
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03709771 is a clinical trial that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT03709771 was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.
Interventions
- DIAGNOSTIC_TEST Ambulatory Blood Pressure Measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2020-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709771
The ClinicalTrials.gov registry entry for NCT03709771 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ambulatory Blood Pressure Measurement is the first listed.
NCT03709771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03709771 about?
NCT03709771 is a clinical study titled "Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease". The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.
What is the current status of trial NCT03709771?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-01-09. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT03709771?
The interventions under investigation include: Ambulatory Blood Pressure Measurement (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03709771?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.